06:59 AM EDT, 07/15/2024 (MT Newswires) -- Novo Nordisk ( NVO ) executives are reportedly scheduled to meet with Democratic US Senate aides on Tuesday to discuss the repercussions of the company's decision to stop selling one of its long-acting insulins in the United States, Reuters reported Saturday, citing two sources familiar with the matter.

In November, Novo Nordisk ( NVO ) said it intended to pull Levemir insulin from the US market by the end of 2024. citing manufacturing constraints, reduced patient access, and the availability of other insulins.

The meeting will reportedly involve aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren.

Novo Nordisk ( NVO ) did not immediately respond to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 143.89, Change: +1.81, Percent Change: +1.27